Whitelab Genomics is a developer of genomics medicines that uses AI-powered in-silico simulations to support target discovery, vector and payload design, genotoxicity assessment, and identification of in vitro and in vivo experimental protocols. The company provides customized computational workflows to help clients accelerate development of target vectors and payloads and reduce time to bring genomic therapies to patients. Founded in 2019 by David Del Bourgo and Julien Cottineau, the company is based in Paris and Cambridge, MA. Its team includes data scientists and computational biologists specialized in AI-driven drug design. Whitelab intends to use new funding to grow its R&D team and expand US operations. No operating metrics beyond the fundraising were disclosed in the article.

Total raised

$10M

Funding rounds

1

Latest round

Series A

Latest activity

Sep 2022